Proteon Pharmaceuticals

Proteon Pharmaceuticals is a Polish biotechnology company specializing in developing bacteriophage-based solutions. The company leverages its patented phage-platform technology to develop products targeting the livestock farming and aquaculture sectors. Moreover, it has operations in four continents and holds numerous international patents.

Proteon offers a portfolio of four commercialized products (BAFCOL, BAFASAL+G, BFASAL, and BAFADOR) with an additional four in the pipeline. These are to modulate the microbiome and offer a natural and effective alternative to traditional antibiotics, focusing on improving on-farm efficiency, sustainability, antimicrobial resistance, and food safety. 

Key customers and partnerships

Proteon aims to license out its technology for designing and delivering phage products to production partners.

Funding and financials

In August 2021, Proteon Pharmaceuticals raised EUR 21 million (~USD 24.6 million) in funding, led by Nutreco, Aqua-Spark, and PFR Life Science, along with other investors. The funds were earmarked for global product rollouts, new product development, and enhancing production capabilities, focusing on integrating AI tools for advanced phage technology development.